Antiatherosclerotic actions of isradipine.
Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing factor, and the subsequent elevation of intracellular adenosine-3',5'-cyclic phosphate and 3',5'-guanosine monophosphate, respectively. These mechanisms have been proven in vitro and in animal models. Preliminary data in humans suggest that these mechanisms have clinical relevance in the long-term treatment of patients as well.
Sinzinger
H
H
Wilhelm Auerswald Atherosclerosis Research Group, Austrian Academy of Sciences, Vienna.
Fitscha
P
P
D001161:Arteriosclerosis / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D006801:Humans; D017275:Isradipine; D050356:Lipid Metabolism
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D017275:Isradipine